BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 29899543)

  • 21. Downregulation of microRNA-630 inhibits cell proliferation and invasion and enhances chemosensitivity in human ovarian carcinoma.
    Zou YT; Gao JY; Wang HL; Wang Y; Wang H; Li PL
    Genet Mol Res; 2015 Jul; 14(3):8766-77. PubMed ID: 26345808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
    Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
    Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma.
    Zhou J; Gong G; Tan H; Dai F; Zhu X; Chen Y; Wang J; Liu Y; Chen P; Wu X; Wen J
    Oncol Rep; 2015 Jun; 33(6):2915-23. PubMed ID: 25962395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner.
    Wang Y; Qiu C; Lu N; Liu Z; Jin C; Sun C; Bu H; Yu H; Dongol S; Kong B
    Int J Oncol; 2018 Jun; 52(6):2130-2142. PubMed ID: 29620165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estrogen receptor-mediated miR-486-5p regulation of OLFM4 expression in ovarian cancer.
    Ma H; Tian T; Liang S; Liu X; Shen H; Xia M; Liu X; Zhang W; Wang L; Chen S; Yu L
    Oncotarget; 2016 Mar; 7(9):10594-605. PubMed ID: 26871282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
    Zhang X; Huang L; Zhao Y; Tan W
    Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues].
    Zhang Q; He XJ; Ma LP; Li N; Yang J; Cheng YX; Cui H
    Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):885-90. PubMed ID: 22340095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
    Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
    Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Herpes virus microRNA expression and significance in serous ovarian cancer.
    Pandya D; Mariani M; McHugh M; Andreoli M; Sieber S; He S; Dowell-Martino C; Fiedler P; Scambia G; Ferlini C
    PLoS One; 2014; 9(12):e114750. PubMed ID: 25485872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
    van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
    Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-493-5p promotes apoptosis and suppresses proliferation and invasion in liver cancer cells by targeting VAMP2.
    Wang G; Fang X; Han M; Wang X; Huang Q
    Int J Mol Med; 2018 Mar; 41(3):1740-1748. PubMed ID: 29328362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
    Wu D; Lu P; Mi X; Miao J
    Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of microRNA-9 mediates cytotoxicity of curcumin against SKOV3 ovarian cancer cells.
    Zhao SF; Zhang X; Zhang XJ; Shi XQ; Yu ZJ; Kan QC
    Asian Pac J Cancer Prev; 2014; 15(8):3363-8. PubMed ID: 24870723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MiR-219-5p inhibits growth and metastasis of ovarian cancer cells by targeting HMGA2.
    Xing F; Song Z; He Y
    Biol Res; 2018 Nov; 51(1):50. PubMed ID: 30474570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.
    Creighton CJ; Fountain MD; Yu Z; Nagaraja AK; Zhu H; Khan M; Olokpa E; Zariff A; Gunaratne PH; Matzuk MM; Anderson ML
    Cancer Res; 2010 Mar; 70(5):1906-15. PubMed ID: 20179198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-219-5p inhibits the proliferation, migration, and invasion of epithelial ovarian cancer cells by targeting the Twist/Wnt/β-catenin signaling pathway.
    Wei C; Zhang X; He S; Liu B; Han H; Sun X
    Gene; 2017 Dec; 637():25-32. PubMed ID: 28890378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance.
    Ye G; Fu G; Cui S; Zhao S; Bernaudo S; Bai Y; Ding Y; Zhang Y; Yang BB; Peng C
    J Cell Sci; 2011 Feb; 124(Pt 3):359-68. PubMed ID: 21224400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma.
    Yu X; Zhang X; Bi T; Ding Y; Zhao J; Wang C; Jia T; Han D; Guo G; Wang B; Jiang J; Cui S
    Tumour Biol; 2013 Dec; 34(6):3501-8. PubMed ID: 23836287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of apoptosis in ovarian cancer cells by miR-493-3p directly targeting AKT2, STK38L, HMGA2, ETS1 and E2F5.
    Kleemann M; Schneider H; Unger K; Bereuther J; Fischer S; Sander P; Marion Schneider E; Fischer-Posovszky P; Riedel CU; Handrick R; Otte K
    Cell Mol Life Sci; 2019 Feb; 76(3):539-559. PubMed ID: 30392041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6.
    Xia B; Yang S; Liu T; Lou G
    Mol Cancer; 2015 Mar; 14():57. PubMed ID: 25889927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.